Table 2.
Results of a Cost-effectiveness Analysis of 3 Cryptococcal Meningitis Induction Regimens for the United States, Using Amphotericin B, Referencing a Common Baseline
| Induction Regimen | Cost ($) | Incremental Cost ($) | Effectiveness (QALY) | Incremental Efficiency (QALY) | ICER ($/QALY) | C/E ($/QALY) |
|---|---|---|---|---|---|---|
| Amphotericin B deoxycholate + fluconazole | $31 197 | Reference | 25.62 | Reference | Reference | $1217 |
| Liposomal amphotericin + fluconazole | $44 605 | $13 408 | 25.62 | 0 | NA | $1741 |
| Amphotericin B deoxycholate for 4 weeks | $58 089 | $26 891 | 24.40 | −1. 22 | –$21 990 | $2380 |
| Liposomal amphotericin for 4 weeks | $83 227 | $52 030 | 24.40 | −1. 22 | –$31 584 | $3411 |
| Amphotericin B deoxycholate + 5FC | $61 714 | $30 517 | 26.90 | 1.28 | $23 842 | $2293 |
| Liposomal amphotericin + 5FC | $75 121 | $43 924 | 26.90 | 1.28 | $34 315 | $2792 |
Abbreviations: 5FC, flucytosine; C/E, cost effectiveness; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-year.